COVID‐19 induced bradyarrhythmia and relative bradycardia: An overview. Issue 4 (14th June 2021)

• Record Type: Journal Article
• Authors: Douedi, Steven; Mararenko, Anton; Alshami, Abbas; Al‐Azzawi, Mohammed; Ajam, Firas; Patel, Swapnil; Douedi, Hani; Calderon, Dawn
• Is Part Of: Journal of arrhythmia. Volume 37:Issue 4(2021)
• Page Start: 888
• Page End: 892
• Publication Date: 2021-06-14
• Subjects: arrythmia -- bradyarrhythmia -- bradycardia -- coronavirus -- COVID‐19; Arrhythmia -- Periodicals; Cardiac pacing -- Periodicals; Arrhythmias, Cardiac; Arrhythmia; Cardiac pacing; Periodicals; Electronic journals; Periodicals; 616.128
• DOI: 10.1002/joa3.12578
• Languages: English
• ISSNs: 1880-4276

Abstract

Abstract: Novel coronavirus 2019 (COVID‐19) has been the focus of the medical community since its emergence in December 2019 and has already infected more than 100 million patients globally. Primarily described to cause a respiratory illness, COVID‐19 has been found to affect almost every organ system. Bradycardia is a newly recognized ramification of COVID‐19 that still has unknown prognostic value. Studies have shown an increase in the incidence of arrhythmias, cardiomyopathies, myocarditis, acute coronary syndromes, and coagulopathies in infected patients as well as an increased risk of mortality in patients with preexisting cardiovascular disease. While the pathogenesis of bradycardia in COVID‐19 may be multifactorial, clinicians should be aware of the mechanism by which COVID‐19 affects the cardiovascular system and the medication side effects which are used in the treatment algorithm of this deadly virus. There has yet to be a comprehensive review analyzing bradyarrhythmia and relative bradycardia in COVID‐19 infected patients. We aim to provide a literature review including the epidemiology, pathogenesis, and management of COVID‐19 induced bradyarrhythmia. Abstract : Bradycardia is a newly recognized ramification of the COVID‐19 that still has unknown prognostic value. Studies have shown an increase in the incidence of arrhythmias, cardiomyopathies, myocarditis, acute coronary syndromes, and coagulopathies in infected patients as well as an increased risk of mortality in patients with preexisting cardiovascular disease. While the pathogenesis of bradycardia in COVID‐19 may be multifactorial, clinicians should be aware of the mechanism by which COVID‐19 affects the cardiovascular system and the medication side effects which are used in the treatment algorithm of this deadly virus.